Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNB2 | O95067 | 2/20 | 0.50 |
| ▸ | CDK1 | P06493 | 2/20 | 0.50 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.50 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.50 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.50 |
| ▸ | CCNB3 | Q8WWL7 | 2/20 | 0.50 |
| ▸ | GSK3A | P49840 | 1/20 | 0.49 |
| ▸ | GSK3B | P49841 | 1/20 | 0.49 |
| ▸ | RIPK1 | Q13546 | 6/20 | 0.47 |
| ▸ | BRD4 | O60885 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | CSF1R | P07333 | 1/20 | 0.46 |
| ▸ | MASP2 | O00187 | 1/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.44 |
| ▸ | KIT | P10721 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.42 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28868920 | 0.84 | ADORA2A (0.48) | GSK3BRIPK1BRD4NPC1RAB9A | |
| SCHEMBL28323721 | 0.83 | CCNB2 (0.51) | CCNB2CDK1CCNB1CCNB3RIPK1 | |
| SCHEMBL17065183 | 0.83 | KIT (0.55) | CCNB2CDK1CCNB1CDK5CDK5R1 | |
| SCHEMBL7230038 | 0.82 | RIPK1 (0.52) | RIPK1CSF1REGFRPDK1 | |
| SCHEMBL24541993 | 0.79 | PDK1 (0.42) | RIPK1CSF1REGFRPDK1 | |
| SCHEMBL30110791 | 0.79 | PRMT5 (0.53) | CCNB2CDK1CCNB1CCNB3RIPK1 | |
| SCHEMBL27412769 | 0.79 | CCNB2 (0.54) | CCNB2CDK1CCNB1CDK5CDK5R1 | |
| SCHEMBL4796192 | 0.78 | NSD3 (0.49) | CCNB2CDK1CCNB1CDK5CDK5R1 | |
| SCHEMBL1772615 | 0.78 | RIPK1 (0.54) | CCNB2CDK1CCNB1CDK5CDK5R1 | |
| SCHEMBL31308645 | 0.78 | KIT (0.47) | CCNB2CDK1CCNB1CDK5CDK5R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9896730-B2 | Use of EMT gene signatures in cancer drug discovery, diagnostics, and treatment | OSI Pharmaceuticals, LLC (US) | 2018-02-20 | — | — | US | disclosed |
| EP-2702173-A1 | USE OF EMT GENE SIGNATURES IN CANCER DRUG DISCOVERY, DIAGNOSTICS, AND TREATMENT | OSI Pharmaceuticals, LLC (US) | 2014-03-05 | — | — | EP | disclosed |
| US-20140057352-A1 | METHODS FOR THE IDENTIFICATION OF AGENTS THAT INHIBIT MESENCHYMAL-LIKE TUMOR CELLS OR THEIR FORMATION | OSI PHARMACEUTICALS LLC (US) | 2014-02-27 | — | — | US | disclosed |
| US-8642834-B2 | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation | OSI Pharmaceuticals, LLC (US) | 2014-02-04 | — | — | US | disclosed |
| WO-2013152252-A1 | COMBINATION ANTI-CANCER THERAPY | OSI Pharmaceuticals, LLC (US) | 2013-10-10 | — | — | WO | disclosed |
| US-20130210026-A1 | BIOLOGICAL MARKERS PREDICTIVE OF ANTI-CANCER RESPONSE TO KINASE INHIBITORS | OSI Pharmaceuticals, LLC | 2013-08-15 | — | — | US | disclosed |
| US-8465912-B2 | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation | OSI Pharmaceuticals, LLC (US) | 2013-06-18 | — | — | US | disclosed |
| US-8377636-B2 | Biological markers predictive of anti-cancer response to kinase inhibitors | OSI Pharmaceuticals, LLC (US) | 2013-02-19 | — | — | US | disclosed |
| US-20120302572-A1 | USE OF EMT GENE SIGNATURES IN CANCER DRUG DISCOVERY, DIAGNOSTICS, AND TREATMENT | AVEO PHARMACEUTICALS, INC. (US) | 2012-11-29 | — | — | US | disclosed |
| WO-2012149014-A1 | USE OF EMT GENE SIGNATURES IN CANCER DRUG DISCOVERY, DIAGNOSTICS, AND TREATMENT | OSI Pharmaceuticals, LLC (US) | 2012-11-01 | — | — | WO | disclosed |
| EP-2134860-A1 | BIOLOGICAL MARKERS PREDICTIVE OF ANTI-CANCER RESPONSE TO KINASE INHIBITORS | OSI Pharmaceuticals, Inc. (US) | 2009-12-23 | — | — | EP | disclosed |
| US-20090274698-A1 | Combination anti-cancer therapy | OSI PHARMACEUTICALS, INC. | 2009-11-05 | — | — | US | disclosed |
| US-20090263397-A1 | Combination anti-cancer therapy | OSI PHARMACEUTICALS, INC. | 2009-10-22 | — | — | US | disclosed |
| WO-2009111067-A2 | METHODS FOR THE IDENTIFICATION OF AGENTS THAT INHIBIT MESENCHYMAL -LIKE TUMOR CELLS OR THEIR FORMATION | OSI PHARMACEUTICALS, INC. (US) | 2009-09-11 | — | — | WO | disclosed |
| US-20090226396-A1 | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation | HALEY JOHN D | 2009-09-10 | — | — | US | disclosed |
| WO-2009009016-A1 | COMBINATION ANTI-CANCER THERAPY | OSI PHARMACEUTICALS, INC. (US) | 2009-01-15 | — | — | WO | disclosed |
| WO-2009008992-A2 | COMBINATION ANTI-CANCER THERAPY COMPRISING AN INHIBITOR OF BOTH MTORC1 AND MT0RC2 | OSI PHARMACEUTICALS INC. (US) | 2009-01-15 | — | — | WO | disclosed |
| US-20080312260-A1 | Biological markers predictive of anti-cancer response to kinase inhibitors | HALEY JOHN D | 2008-12-18 | — | — | US | disclosed |
| WO-2008127719-A1 | BIOLOGICAL MARKERS PREDICTIVE OF ANTI-CANCER RESPONSE TO KINASE INHIBITORS | OSI PHARMACEUTICALS, INC. (US) | 2008-10-23 | — | — | WO | disclosed |
| US-7253166-B2 | 6-phenyl-7H-pyrrolo[2,3-d]pyrimidine compounds that induce neuronal differentiation in embryonic stem cells | IRM LLC (BM) | 2007-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090263397-A1 | Combination anti-cancer therapy | IGF1R, IGFBP6, IGFBP1 | CCNB2 1040/4885CDK1 154/4885CCNB1 246/4885 |
| US-20120302572-A1 | USE OF EMT GENE SIGNATURES IN CANCER DRUG DISCOVERY, DIAGNOSTICS, AND TREATMENT | IGF1R, IGFBP1, EGFR | CCNB2 2589/4885CDK1 1066/4885CCNB1 2408/4885 |
| US-20090274698-A1 | Combination anti-cancer therapy | MTOR, RICTOR, AKT1 | CCNB2 1493/4885CDK1 126/4885CCNB1 988/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.